USPTO serial 88214189
ADAP
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRIEDMAN, LESLEE ANN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ADAP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Monmouth Junction, NJ
Monmouth Junction, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Julian D. Gonzalez
1 DEERPARK DRIVE, SUITE RMONMOUTH JUNCTION, NJ 08852UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays for research purposes; Biological and chemical reagents used for non-medical research purposes, namely, in vitro and in vivo scientific use, the testing of bodily fluids, and the detecting and analyzing of cells, proteins, small molecules, and nucleotides; Chemical test kits for the detection and identification of nucleic acids, namely, DNA and RNA in a sample for laboratory or research use | ACTIVE | — |
| 005 | Biological and chemical testing kits for personal wellness in the nature of diagnostic test kits consisting primarily of medical diagnostic reagents and assays for the detection of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents and assays for testing cells, proteins, small molecules, nucleotides, and nucleic acids; Medical diagnostic reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic biomarker reagents for medical purposes | ACTIVE | — |
| 010 | Medical diagnostic apparatus for testing cells, tissue and biomolecules, in the nature of proteins, small molecules, cells, and nucleic acids; Medical devices for obtaining bodily fluid samples; Medical diagnostic instruments for the analysis of bodily fluids; Medical apparatus for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases, and other tissue-based diagnostic testing, cytology, and cell-based testing; medical diagnostic devices for personal wellness, namely, point-of-care diagnostic devices, at-home diagnostic devices, and portable health monitoring devices that detect health conditions and diseases in the nature of cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical diagnostic instruments, namely, instruments for medical testing in the nature of the detection and identification of nucleic acids, namely, DNA and RNA in a sample; all of the aforesaid not including medical and surgical ultrasonic diagnostic and therapy apparatus and parts thereof, ultrasonic echography devices, and lithotriptors and parts thereof | ACTIVE | — |
| 044 | Medical services; Medical assistance; Medical consultations; Medical counseling; Medical information; Healthcare services; Diagnostic services, namely, medical testing for diagnostic purposes; Wellness consulting services; Medical services, medical assistance, medical consultations, medical counseling, medical information, healthcare testing in the nature of diagnostic testing, and wellness counseling services, namely, in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and other tissue-based diagnostic testing, cytology, and cell-based testing; Medical services for the detection and identification of cells, proteins, small molecules, and nucleic acids in a sample for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Essenlix Corporation
- Other trademarks owned by Essenlix Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named ADAP
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 25, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 24, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 22, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 22, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 22, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 24, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 22, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 22, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 22, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 9, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 7, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 7, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 7, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 2, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 1, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 31, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 10, 2020 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jul 10, 2020 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Jul 10, 2020 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jul 10, 2020 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jun 24, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 24, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 29, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 29, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 9, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 19, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 19, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 19, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 4, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 4, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 29, 2019 | ALIE | ASSIGNED TO LIE | — |
| Aug 21, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 28, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 20, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 6, 2018 | NWAP | NEW APPLICATION ENTERED | — |